Roivant Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Roivant Sciences's estimated annual revenue is currently $57M per year.
- Roivant Sciences's estimated revenue per employee is $193,750
- Roivant Sciences's total funding is $2.1B.
- Roivant Sciences's current valuation is $7B. (May 2021)
Employee Data
- Roivant Sciences has 294 Employees.
- Roivant Sciences grew their employee count by -7% last year.
Roivant Sciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | Chief Accounting Officer | Reveal Email/Phone |
3 | Chief Medical Officer-in-Residence | Reveal Email/Phone |
4 | Chief Staff | Reveal Email/Phone |
5 | CEO | Reveal Email/Phone |
6 | VP Research, Head Drug Discovery | Reveal Email/Phone |
7 | VP, Clinical Development | Reveal Email/Phone |
8 | VP, Investments | Reveal Email/Phone |
9 | Head Information Security | Reveal Email/Phone |
10 | Head IT Business Solutions and Procurement | Reveal Email/Phone |
Roivant Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Roivant Sciences?
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants ? nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. We have built 15 Vants to date and have raised over $3 billion to pursue our mission. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson?s disease, diabetes, sickle cell disease, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
keywords:N/A
$2.1B
Total Funding
294
Number of Employees
$57M
Revenue (est)
-7%
Employee Growth %
$7B
Valuation
N/A
Accelerator
Roivant Sciences News
Roivant Sciences Ltd. (NASDAQ:ROIV) Expected to Announce Quarterly Sales of $15.41 Million. Posted by admin on Apr 16th, 2022.
Wall Street brokerages predict that Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) will report ($0.25) earnings per share (EPS) for the...
... 2022 (GLOBE NEWSWIRE) -- Roivant Social Ventures, a nonprofit philanthropic social impact organization launched by Roivant Sciences,...
BASEL, Switzerland and LONDON and NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Roivant Sciences Ltd. ("Roivant" or the "Company"), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the fiscal quarter en ...
NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health, the leader in clinical data exchange, have signed a definitive merger agreement. The combine ...
Other Companies in Basel
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $104M | 308 | 7% | N/A |
#2 | $93M | 338 | 32% | N/A |
#3 | N/A | 373 | 12% | N/A |
#4 | $60.3M | 389 | -5% | N/A |
#5 | $109.2M | 397 | 29% | N/A |